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In this article, we describe a case of bacteraemic pneumonia caused by Neisseria meningitidis serogroup Y.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.A 94-year-old man sought medical care for left sided chest pain
and difﬁculty in breathing that began 1 day before admission. He
had been healthy until 4 days before admission, when sore throat,
rhinorrhea, mild cough, and muscle pain. He had medical history of
ischemic cardiopathy.
Onphysical examination, heappeared illwith respiratorydistress.
The respiratory rate was 60 per minute, the heart rate was 120 beats
per minute, the temperature was 38.2 C, and the blood oxygen
saturation was 88% in room air. The blood pressure was 94/68 mm.
The heart sounds were normal. The abdomen was soft without
hepatosplenomegaly. His neck was supple without signs of menin-
geal irritation. On chest auscultation, coarse sounds with crackles
over both bases were heard. Chest radiograph showed diffuse
homogeneous inﬁltration in the upper lung zones and a conﬂuent
area in the right middle lobe without pleural effusion. (Fig. 1).
His white blood cell (WBC) count on admission was 4300
cells/mm3 (neutrophils 90%, lymphocytes 6%) and C-reactive
protein was 181 mg/dL (reference: <5 mg/dL). The hemoglobin
was 14.6 g/dL, and the platelets were 165 x 103/mm3. The venous
pH was 7.38, the PCO2 was 38.1 mm/Hg, and the base excess
was 2.2. The lactate concentration was 2.30 mmol/L. The serum
creatinine was 1.20 mg/dL, and the serum urea nitrogen was
43 mg/dL. The total protein was 6.9 g/dL. The aspartate amino-
transferase was 20 U/L, and the alanine aminotransferase was
14 U/L. The total bilirubin was 0.7 mg/dL.
He was admitted in pneumology unit with a diagnosis of
community pneumonia and empirical intravenous regimen of
clarithromycin (500 mg/day) and ceftriaxone (2 g/day) was
commenced before the microbiology results were reported.
Blood cultures taken during the patient’s febrile episode were
incubated in an automated BACTEC FX system [Becton Dickinson,(M.P. Romero-Gomez).
-NC-ND license.Frank*lin Lakes, NJ, USA]. Both aerobic and anaerobic bottle cultures
became positive after 3 days of incubation for gram-negative
diplococcus. The organism was subcultured onto sheep blood
agar, chocolate agar and Brucella blood agar. The sheep blood agar
and chocolate blood agar plates were incubated at 35 C in atmo-
sphere containing 5% CO2 for 48 h. The Brucella blood agar was
incubated at 35 C in atmosphere anaerobic for two days.
The organism isolated from blood culture at admission was
oxidase, catalase and ONPG positive, and utilized glucose, maltose
and lactose. This organism was identiﬁed as Neisseria meningitidis
by the VITEK NHI Identiﬁcation card (bioMerieux) (identiﬁcation
proﬁle 10520, 99% identity) and by matrix-assisted laser desorp-
tion/ionisation time-of-ﬂight (MALDI-TOF) mass spectrometry. The
isolates are serogrouped by agglutination using commercial anti-
sera Difco (Detroit, MI, USA).
Susceptibility testing was performed with the Wider system
(Fco. Soria Melguizo) and the isolate was sensitive to cefotaxime
(CMI 0.03 mg/mL), meropenem, quinolonas, cloramfenicol and
rifampicina and the susceptibility was intermediate to penicillin
and ampicilin. Treatment was accordingly changed to ceftriaxone
2 g/24 h given intravenously.
The fever gradually subsided after 2 days of cefotaxime, and the
patient’s general condition gradually improved. The patient was
discharged after 8 days of antibiotics.
1. Discussion
N. meningitidis is a Gram-negative aerobic diplococcus, which is
a normal commensal of the human nasopharynx. Meningococcal
meningitis and meningococcemia are the 2 clinical syndromes with
which it is traditionally associated, resulting from invasion of the
local tissues into the bloodstream. It may also cause conjunctivitis,
pharyngitis, pneumonia, pericarditis, septic arthritis, and urethritis.6
This organism is classiﬁed into 13 serogroups, and most meningo-
coccal disease is caused by strains that express 1 of the 5 types
Fig. 1. Chest radiograph showed diffuse homogeneous inﬁltration in the upper lung
zones and a conﬂuent area in the right middle lobe without pleural effusion.
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serogroups B and C have been responsible for themajority of invasive
meningococcal disease in Europe.
In the mid-1990s, the incidence of disease due to serogroup Y
increased substantially in the United States (US).1,8 During the last
decade, there has also been an increase of meningococcal disease
caused by serogroup Y in Canada and Colombia.9,10 In addition,
some northern European countries, displayed higher proportions of
disease caused by this serogroup: for example, in Norway in 2009
and 2010, the proportion was 31%; in Finland, it was 38% in 2010
and in Sweden, the proportionwas of the 39%, with an incidence of
0.23 per 100,000 population during 2010.7
Meningococcal pneumonia is infrequent, is estimated to occur
in <5%e15% of patients with invasive meningococcal disease,
although the precise incidence is difﬁcult to establish because of
uncertainty in establishing the cause of pneumonia.2,3 Serogroup Y
is more likely than other serogroups to be associated with pneu-
monia.3 Blood or pleural cultures that yieldN. meningitidis establish
the diagnosis with certainty.
Meningococcal colonization of the nasopharyngeal mucosae is
a critical initial step in the pathogenesis of systemic infection.
Several cell surface structures have been identiﬁed that function as
adhesins in attachment of meningococci to respiratory epithelial
cells. After nasopharyngeal colonization, microaspiration of upper
respiratory tract secretions containing N. meningitidis probably
occurs, with the subsequent development of pneumonia. Which
virulence factors are operative in the production of lung infection
and whether they are unique to serogroup Y meningococci are
unknown. In addition, the conditions accounting for the increase in
serogroup Y infections remain undeﬁned.2Other authors have described a predilection of serogroup Y
meningococcus for causing respiratory illness, including a large
outbreak of predominantly respiratory. Smilack et al. reported
a military outbreak that included 12 cases of serogroup Y menin-
gococcal disease (SYMD) among members of an army combat
training unit. In this series, 5 patients had meningococcemia, 5 had
meningitis, and 2 presented with primary meningococcal pneu-
monia.4 Subsequently, a case series of SYMD was reported in
a group of US Air Force recruits in 1971e1974.6 In that series, the
predominant manifestation of serogroup Y disease was respiratory;
68 (77%) of 88 patients had meningococcal pneumonia, docu-
mented by transtracheal aspirates in 94% of the cases. Only 4 (6%) of
the 68 patients with pneumonia had positive blood cultures.5
Among the patients with pneumonia, the response to antibiotic
therapy was prompt; 93% of the patients were afebrile within 3
days of antibiotic therapy.2 The outcome of meningococcal pneu-
monia when treated is generally favorable, but the diagnosis
requires a high index of suspicion, testing of respiratory samples,
and blood cultures.
In conclusion, we report a case of bacteraemic pneumonia
caused by N. meningitidis serogroup Y with reduced susceptibility
to penicillin in an adult patient.
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